Gyre Therapeutics, Inc. (NASDAQ:GYRE) just released a solid earnings report, and the stock displayed some strength. Despite this, our analysis suggests that there are some factors weakening the ...
Unsurprisingly, Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) stock price was strong on the back of its healthy earnings report. However, we think that shareholders may be missing some concerning details in ...
Gyre Therapeutics reported Q1 2025 revenue of $22.1 million and provided updates on clinical trials and product launches. Gyre Therapeutics reported Q1 2025 revenue of $22.1 million and a GAAP basic ...
GYRE is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of GYRE shares has decreased $0.08 since the market last closed. This is a 1.18 ...
Zacks.com on MSN
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates
Gyre Therapeutics, Inc. (GYRE) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.01 per share a year ago.
Gyre Therapeutics is an under-the-radar biotech company that achieved its listing on the Nasdaq through a merger between Catalyst Biosciences and GNI Group. Gyre focuses on developing small-molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results